Skip to main content Accessibility help
×
Home

The diagnosis, clinical findings and treatment options for Parkinson's disease patients attending a tertiary referral voice clinic

  • N Gibbins (a1), R Awad (a2) (a3), S Harris (a2) and A Aymat (a1)

Abstract

Background:

Parkinson's disease is a degenerative disorder of the central nervous system, mainly affecting motor functions including the voice. The aetiology of dysphonia changes throughout the course of disease progression.

Objectives:

This study aimed to determine the laryngeal changes seen in early-, mid- and late-stage Parkinson's disease. Thirteen patients with Parkinson's disease are presented, representing the largest series of voice patients with Parkinson's disease seen in a voice clinic in the literature.

Method:

Age, gender, severity of handicap caused by voice disorder and possible associated reflux symptoms were examined.

Results:

Laryngeal function appeared to change gradually with progression of the disease, and may have been affected by the presence of pre-existing laryngeal pathology.

Conclusion:

Laryngeal function in Parkinson's disease appears to go through a series of changes that may be helped by both therapeutic and surgical interventions. These patients should be treated within the confines of a voice clinic multidisciplinary model.

Copyright

Corresponding author

Address for correspondence: Mr N Gibbins, Department of Otolaryngology, University Hospital Lewisham, Lewisham High Street, London SE13 6LH, UK E-mail: nicholas.gibbins@nhs.net

Footnotes

Hide All

Presented as a poster at the 15th British Academic Conference of Otolaryngology, 8–10 July 2015, Liverpool, UK.

Footnotes

References

Hide All
1 Ramig, LO, Fox, C, Sapir, S. Speech treatment for Parkinson's disease. Expert Rev Neurother 2008;8:299311
2 Ramig, L, Meyer, T, Fox, C, Blitzer, A, Tagliati, M. Laryngeal function in individuals with Parkinson's disease. Perspectives on Voice and Voice Disorders 2005;15:915
3 Pitcairn, T, Clemie, S, Gray, J, Pentland, B. Non-verbal cues in the self-presentation of parkinsonian patients. Br J Clin Psychol 1990;29:177–84
4 Pitcairn, T, Clemie, S, Gray, J, Pentland, B. Impressions of parkinsonian people from their recorded voices. Br J Clin Psychol 1990;25:8592
5 Miller, N, Noble, E, Jones, D, Burn, D. Life with communication changes in Parkinson's disease. Age Ageing 2006;35:235–9
6 Sapir, S, Ramig, LO, Hoyt, P, Countryman, S, O'Brien, C, Hoehn, M. Speech loudness and quality 12 months after intensive voice treatment (LSVT®) for Parkinson's disease: a comparison with an alternative speech treatment. Folia Phoniatr Logop 2002;54:296303
7 Berardelli, A, Rothwell, JC, Thompson, PD, Hallett, M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 2001;124:2131–46
8 Ramig, LO, Fox, C, Sapir, S. Parkinson's disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment. Semin Speech Lang 2004;25:169–80
9 Hammer, MJ, Barlow, SM. Laryngeal somatosensory deficits in Parkinson's disease: implications for speech respiratory and phonatory control. Exp Brain Res 2010;201:401–9
10 Hanson, DG, Gerratt, BR, Ward, PH. Cinegraphic observations of laryngeal function in Parkinson's disease. Laryngoscope 1984;94:348–53
11 Perez, KS, Ramig, LO, Smith, ME, Dromey, C. The Parkinson larynx: tremors and videostroboscopic findings. J Voice 1996;10:354–61
12 Stelzig, Y, Hochhaus, W, Gall, V, Henneberg, A. Laryngeal manifestations in patients with Parkinson disease [in German]. Laryngorhinootologie 1999;78:544–51
13 Yücetürk, AV, Yilmaz, H, Eğrilmez, M, Karaca, S. Voice analysis and videolaryngostroboscopy in patients with Parkinson's disease. Eur Arch Otorhinolaryngol 2002;259:290–3
14 Radad, K, Gille, G, Rausch, W. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005;57:701–12
15 Goberman, A, Coelho, C, Robb, M. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J Commun Disord 2002;35:217–39
16 Sanabria, J, Ruiz, PG, Gutierrez, R, Marquez, F, Escobar, P, Gentil, M et al. The effect of levodopa on vocal function in Parkinson's disease. Clin Neuropharmacol 2001;24:99102
17 Jiang, J, Lin, E, Wang, J, Hanson, DG. Glottographic measures before and after levodopa treatment in Parkinson's disease. Laryngoscope 1999;109:1287–94
18 Larson, K, Ramig, LO, Scherer, RC. Acoustic and glottographic voice analysis during drug-related fluctuations in Parkinson's disease. J Med Speech Lang Pathol 1994;2:211–26
19 Kompoliti, K, Wang, QE, Goetz, CG, Leurgans, S, Raman, R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 2000;54:458–62
20 Trail, M, Fox, C, Ramig, LO, Sapir, S, Howard, J, Lai, EC. Speech treatment for Parkinson's disease. NeuroRehabilitation 2005;20:205–21
21 Biary, N, Pimental, PA, Langenberg, PW. A double-blind trial of clonazepam in the treatment of parkinsonian dysarthria. Neurology 1988;38:255–8
22 Kompoliti, K, Wang, QE, Goetz, CG, Leurgans, S, Raman, R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 2000;54:458–62
23 Baker, K, Ramig, LO, Johnson, A, Freed, C. Preliminary speech and voice analysis following foetal dopamine transplants in 5 people with Parkinson's disease. J Speech Hear Res 1997;20:615–26
24 Ghika, J, Ghika-Schmid, F, Fankhauser, H, Assal, G, Vingerhoets, F, Abanese, A et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects, report of four cases and review of the literature. J Neurosurg 1999;9:313–21
25 Krack, P, Batir, A, VanBiercom, N, Charbardes, S, Fraix, V, Ardouin, C et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;20:1925–34
26 Törnqvist, AL, Schalén, L, Rehncrona, S. Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson's disease treated with subthalamic deep brain stimulation. Mov Disord 2005;20:416–23
27 Ramig, LO, Sapir, S, Countryman, S, Pawlas, AA, O'Brien, C, Hoehn, M et al. Intensive voice treatment (LSVT®) for people with Parkinson's disease: a 2 year follow-up. J Neurol Neurosurg Psychiatr 2001;71:493–8
28 Ramig, L, Sapir, S, Fox, C, Countryman, S. Changes in vocal intensity following intensive voice treatment (LSVT) in people with Parkinson's disease: a comparison with untreated people and with normal age-matched controls. Mov Disord 2001;16:7983
29 Fox, CM, Ramig, LO, Ciucci, MR, Sapir, S, McFarland, DH, Farley, BG. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin Speech Lang 2006;27:283–99
30 Smith, ME, Ramig, LO, Dromey, C, Perez, KS, Samandari, R. Intensive voice treatment in Parkinson disease: laryngostroboscopic findings. J Voice 1995;9:453–9
31 Luschei, ES, Ramig, LO, Baker, KL, Smith, ME. Discharge characteristics of laryngeal single motor units during phonation in young and older adults and in persons with Parkinson disease. J Neurophysiol 1999;81:2131–9
32 Perez, KS, Ramig, LO, Smith, ME, Dromey, C. The Parkinson larynx: tremor and videostroboscopic findings. J Voice 1996;10:354–61
33 Baker, KK, Ramig, LO, Luschei, ES, Smith, ME. Thyroarytenoid activity muscle associated with hypophonia in Parkinson's disease and aging. Neurology 1998;51:1592–8
34 Ramig, LO, Countryman, S, Thompson, LL, Horii, Y. Comparison of two forms of intensive speech treatment for Parkinson disease. J Speech Hear Res 1995;38:1232–51
35 Ramig, LO, Dromey, C. Aerodynamic mechanisms underlying treatment-related changes in vocal intensity in patients with Parkinson's disease. J Speech Hear Res 1996;39:798807

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed